Zhu Mingyue, Zhou Guxin, Chang Fangyuan, Liu Jin
Department of Obstetrics and Gynecology, The Affiliated Hospital of Jiangsu Vocational College of Medicine, KANGFU West Road, Dongtai City, Jiangsu, 224200, China.
Open Med (Wars). 2025 May 13;20(1):20251174. doi: 10.1515/med-2025-1174. eCollection 2025.
The immune microenvironment of ovarian cancer is crucial in its progression. Recent studies highlight the significant role of MZB1 in shaping the tumor immune microenvironment (TIME), although its specific function in ovarian cancer remains unclear.
We analyzed 381 ovarian cancer samples from the TCGA database, along with additional samples from GEO and single-cell datasets. Differentially expressed genes (DEGs) were identified using DESeq2. Various algorithms were applied to assess the relationship between MZB1 and the TIME. Cell proliferation was measured using the CCK-8 assay, while cell migration was evaluated using the wound healing assay. Furthermore, a nomogram predicting overall survival was developed based on multivariable Cox regression results.
Our results indicated a positive correlation between high MZB1 expression and improved clinical prognosis. Additionally, higher MZB1 expression was linked to increased immune cell infiltration within the TIME. Elevated MZB1 levels inhibited the migration and proliferation of SKOV3 cells. The nomogram's C-index was 0.702, and its calibration curve demonstrated good calibration, indicating satisfactory discrimination and accuracy in predicting patient outcomes.
This study comprehensively analyzes MZB1's role in the TIME of ovarian cancer. MZB1 is a promising prognostic marker and a potential target for personalized treatment.
卵巢癌的免疫微环境在其进展过程中至关重要。近期研究强调了MZB1在塑造肿瘤免疫微环境(TIME)中的重要作用,尽管其在卵巢癌中的具体功能仍不清楚。
我们分析了来自TCGA数据库的381份卵巢癌样本,以及来自GEO和单细胞数据集的其他样本。使用DESeq2鉴定差异表达基因(DEG)。应用多种算法评估MZB1与TIME之间的关系。使用CCK-8法测量细胞增殖,同时使用伤口愈合试验评估细胞迁移。此外,基于多变量Cox回归结果开发了预测总生存的列线图。
我们的结果表明,高MZB1表达与改善的临床预后呈正相关。此外,较高的MZB1表达与TIME内免疫细胞浸润增加有关。MZB1水平升高抑制了SKOV3细胞的迁移和增殖。列线图的C指数为0.702,其校准曲线显示出良好的校准,表明在预测患者预后方面具有令人满意的区分度和准确性。
本研究全面分析了MZB1在卵巢癌TIME中的作用。MZB1是一种有前景的预后标志物和个性化治疗的潜在靶点。